/ELAB
ELAB Stock - PMGC Holdings Inc.
Healthcare|BiotechnologyNASDAQ
$2.26+3.67%
+$0.08 (+3.67%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.49
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ELAB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.24 – $2.28
TARGET (TP)$2.60
STOP LOSS$2.08
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.30
52W High$99.96
52W Low$2.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.47M | $1.71M | $766,277 | $827 | N/A |
| Gross Profit | $1.80M | $1.13M | $447,309 | $-2,018 | N/A |
| Gross Margin | 72.8% | 66.2% | 58.4% | -244.0% | N/A |
| Operating Income | $-1,866,566 | $-3,760,081 | $-1,788,292 | $-785,060 | $-221,844 |
| Net Income | $-6,245,737 | $-4,301,517 | $-1,800,268 | $-784,739 | $-222,910 |
| Net Margin | -253.1% | -251.2% | -234.9% | -94889.8% | N/A |
| EPS | $-274.68 | $-1961.37 | $-0.67 | $-0.29 | $-0.08 |
Company Overview
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ELABBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-4.95
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-4.95 | — | — |
Q3 2025 | Aug 12, 2025 | — | $-1.61 | — | — |
Q2 2025 | May 14, 2025 | — | $-2.90 | — | — |
Q2 2025 | Apr 4, 2025 | — | $-99.99 | — | — |
Q4 2024 | Nov 13, 2024 | — | $-97.97 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-111.97 | — | — |
Q2 2024 | May 15, 2024 | — | $-111.97 | — | — |
Q1 2024 | Mar 29, 2024 | — | $-111.97 | — | — |
Q4 2023 | Dec 11, 2023 | — | $-0.08 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.94 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.79 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.24 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.18 | — | — |
Latest News
NorthStrive Biosciences Initiates Phase III Of AI Development Program With Yuva Biosciences Under Development And License Agreement
📈 PositiveBenzinga•Dec 17, 2025, 12:37 PM
PMGC Holdings Subsidiary Completes International Traffic In Arms Regulations Registration And Is In Compliance With ITAR
📈 PositiveBenzinga•Oct 30, 2025, 12:13 PM
PMGC Holdings Operating Subsidiary, AGA Precision Systems LLC , Reports Sales Backlog Over $711K In Current Orders Logged Onto Material Requirements Planning System
📈 PositiveBenzinga•Oct 20, 2025, 11:31 AM
PMGC Holdings' Northstrive Biosciences Completes Phase II Of AI Development Program With Strategic Partner Yuva Biosciences
📈 PositiveBenzinga•Sep 29, 2025, 11:20 AM
PMGC Holdings' Northstrive Biosciences Completes Phase II Of AI Development Program With Strategic Partner Yuva Biosciences
📈 PositiveBenzinga•Sep 4, 2025, 01:56 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 29, 2025, 11:50 PM
PMGC Holdings To Implement 1-For-3.5 Reverse Stock Split Of Common Shares, Effective Sept. 2, 2025 At Market Open
📉 NegativeBenzinga•Aug 28, 2025, 02:33 PM
PMGC signs letter of intent to acquire a US-based electronics manufacturing company
📈 PositiveSeeking Alpha•Jun 9, 2025, 12:43 PM
PMGC Holdings to acquire a U.S.-based custom IT packaging company; shares fall
📉 NegativeSeeking Alpha•Apr 16, 2025, 12:15 PM
Frequently Asked Questions about ELAB
What is ELAB's current stock price?
PMGC Holdings Inc. (ELAB) is currently trading at $2.26 per share. The stock has moved +3.67% today.
What is the analyst price target for ELAB?
No analyst price targets are currently available for this stock.
What sector is PMGC Holdings Inc. in?
PMGC Holdings Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ELAB's market cap?
PMGC Holdings Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ELAB pay dividends?
No, PMGC Holdings Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATXI
Avenue Therapeutics, Inc.
$0.65
Mkt Cap: $0.0B
BCTXZ
BriaCell Therapeutics Corp. Warrant
$0.39
Mkt Cap: $0.0B
DRMA
Dermata Therapeutics, Inc.
$2.14
Mkt Cap: $0.0B
MLEC
Moolec Science S.A.
$0.33
Mkt Cap: $0.0B
NCEL
NewcelX Ltd.
$2.60
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
VRAX
Virax Biolabs Group Limited
$0.39
Mkt Cap: $0.0B
WINT
Windtree Therapeutics, Inc.
$0.04
Mkt Cap: $0.0B
XRTX
XORTX Therapeutics Inc.
$0.60
Mkt Cap: $0.0B
Explore stocks similar to ELAB for comparison